CTNNB1 and colorectal cancer: The high frequency of beta‐catenin alterations and Wnt pathway activation in Sertoli cell tumours NOS suggests that they could respond to Wnt pathway inhibitors that are currently being assessed in clinical trials (mostly for colorectal cancer).138